AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Xbrane Biopharma

Major Shareholding Notification Dec 13, 2023

3128_iss_2023-12-13_a63fc272-7f60-40a0-8015-2e19a1d4fbbd.pdf

Major Shareholding Notification

Open in Viewer

Opens in native device viewer

Issuer Xbrane Biopharma AB

Holder

Avanza Bank Holding AB för Försäkringsaktiebolaget Avanza Pension

Instrument
------------
Instrument Aktier
Before the transaction
Shares Data not given
Data not given
Voting rights
Transaction
Reason for major shareholding notification Share loan
Date 12/12/2023
Limit for number of shares 5 %
Limit for number of votes 5 %
After the transaction
Quantity
Shares 1,529,443
Directly held voting rights 0
Indirectly held voting rights 1,529,443
Percentage
Directly held shares 5.13057 %
Directly held voting rights 0 %
Indirectly held voting rights 5.13057 %

Resulting distribution of total holdings

Percentage of voting
rights:
Number of underlying
shares:
Shares 5.13057 % 1,529,443
Instruments - FITA Ch. 4, section 2, first
paragraph, line 2
Instruments - FITA Ch. 4, section 2,
first paragraph, line 3
- Physically settled
- Cash settled 0.3212 % 95,750
Total 5.45177 % 1,625,193

Group total holdings

Voting rights 1,625,193 Percentage of voting rights 5.45177

Notes (other relevant informations according to law)

Aktierna, samt övriga instrument enligt LHF 4 kap, 2§ första stycket 1 och finansiella instrument enligt LHF 4 kap. 2§ första stycket 3 innehas av Försäkringsaktiebolaget Avanza Pension som är ett helägt dotterbolag till Avanza Bank Holding AB (publ). Angivet gränsvärde har överskridits på grund av retur av utlånade aktier.

Published

13/12/2023 10:35

Contact

Name Marie Andersson

Email [email protected]

*Source of information has chosen not to submit the data

[email protected] Tfn 08-408 980 37 Fax 08-24 39 25

Talk to a Data Expert

Have a question? We'll get back to you promptly.